[{"id":"beb344ab-95cf-420e-8ccd-b61bc4f7a537","acronym":"","url":"https://clinicaltrials.gov/study/NCT07097363","created_at":"2025-08-02T14:05:17.045Z","updated_at":"2025-08-02T14:05:17.045Z","phase":"Phase 2","brief_title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT07097363","lead_sponsor":"University of Washington","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 05/31/2030","primary_completion_date":" 05/31/2030","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-07-31"},{"id":"44bc5480-d166-44d8-a132-2ee768e67fe6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07069699","created_at":"2025-07-19T14:11:58.704Z","updated_at":"2025-07-19T14:11:58.704Z","phase":"Phase 1/2","brief_title":"Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene","source_id_and_acronym":"NCT07069699","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pidnarulex (CX-5461)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/19/2025","start_date":" 09/19/2025","primary_txt":" Primary completion: 09/19/2027","primary_completion_date":" 09/19/2027","study_txt":" Completion: 09/19/2027","study_completion_date":" 09/19/2027","last_update_posted":"2025-07-17"},{"id":"68f3baae-dc4f-43a6-80f0-573ab27bebb5","acronym":"ViPOR","url":"https://clinicaltrials.gov/study/NCT03223610","created_at":"2021-01-18T15:54:35.735Z","updated_at":"2025-02-25T13:39:32.188Z","phase":"Phase 1/2","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT03223610 - ViPOR","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 02/09/2018","start_date":" 02/09/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"ba0b6173-d6ba-4d9f-b7a6-14e36795d0f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02337985","created_at":"2021-01-18T11:06:20.660Z","updated_at":"2025-02-25T16:36:30.633Z","phase":"Phase 1","brief_title":"Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02337985","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • etoposide oral • vincristine • prednisone • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 11/20/2015","start_date":" 11/20/2015","primary_txt":" Primary completion: 10/02/2025","primary_completion_date":" 10/02/2025","study_txt":" Completion: 10/02/2025","study_completion_date":" 10/02/2025","last_update_posted":"2025-02-06"},{"id":"e7cf2c99-6cfe-4015-9ca9-b9a242d379a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04739813","created_at":"2021-02-05T13:56:26.764Z","updated_at":"2025-02-25T16:38:14.078Z","phase":"Phase 1","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04739813","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • UGT1A1","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation","tags":["BCL2 • BCL6 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/09/2021","start_date":" 07/09/2021","primary_txt":" Primary completion: 10/29/2025","primary_completion_date":" 10/29/2025","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2025-02-06"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"d062a33d-5d42-4b72-844d-d38648c52ca1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04464200","created_at":"2022-02-25T20:53:07.117Z","updated_at":"2025-02-25T14:51:50.702Z","phase":"Phase 1","brief_title":"19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers","source_id_and_acronym":"NCT04464200","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/06/2020","start_date":" 07/06/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-08-23"},{"id":"ccaab729-08e3-4b0f-ae17-a92ba3b288af","acronym":"","url":"https://clinicaltrials.gov/study/NCT02996773","created_at":"2021-01-18T14:44:29.668Z","updated_at":"2025-02-25T16:24:52.034Z","phase":"Phase 1","brief_title":"Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine","source_id_and_acronym":"NCT02996773","lead_sponsor":"University of Arizona","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/29/2016","start_date":" 11/29/2016","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 08/25/2025","study_completion_date":" 08/25/2025","last_update_posted":"2024-07-11"},{"id":"b2736ad5-0c4c-46cb-878a-ca7131168d3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00001337","created_at":"2021-01-17T22:44:38.987Z","updated_at":"2024-07-02T16:34:25.642Z","phase":"Phase 2","brief_title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00001337","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Completed","enrollment":" Enrollment 348","initiation":"Initiation: 05/08/1993","start_date":" 05/08/1993","primary_txt":" Primary completion: 05/24/2024","primary_completion_date":" 05/24/2024","study_txt":" Completion: 05/24/2024","study_completion_date":" 05/24/2024","last_update_posted":"2024-06-17"},{"id":"15d10f06-e62d-4c96-9c37-1d6b5cfefc74","acronym":"NCI-2014-01707","url":"https://clinicaltrials.gov/study/NCT02199184","created_at":"2021-01-18T10:16:59.275Z","updated_at":"2024-07-02T16:34:27.417Z","phase":"Phase 2","brief_title":"Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02199184 - NCI-2014-01707","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 01/14/2015","start_date":" 01/14/2015","primary_txt":" Primary completion: 02/17/2023","primary_completion_date":" 02/17/2023","study_txt":" Completion: 02/17/2023","study_completion_date":" 02/17/2023","last_update_posted":"2024-06-11"},{"id":"8258969e-d88e-4ec9-8ff8-f46b03ce6829","acronym":"SGR-1505-101","url":"https://clinicaltrials.gov/study/NCT05544019","created_at":"2022-09-16T14:56:40.430Z","updated_at":"2024-07-02T16:34:37.249Z","phase":"Phase 1","brief_title":"Study of SGR-1505 in Mature B-Cell Neoplasms","source_id_and_acronym":"NCT05544019 - SGR-1505-101","lead_sponsor":"Schrödinger, Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SGR-1505"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 04/10/2023","start_date":" 04/10/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-06-07"},{"id":"e6bd139e-7d5b-486d-888f-481618f10fed","acronym":"LONCA","url":"https://clinicaltrials.gov/study/NCT05270057","created_at":"2022-03-08T16:52:28.981Z","updated_at":"2024-07-02T16:34:59.173Z","phase":"Phase 1","brief_title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","source_id_and_acronym":"NCT05270057 - LONCA","lead_sponsor":"Medical College of Wisconsin","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-06-04"},{"id":"14b28ae8-831d-4306-9aa4-5c102afbfa3f","acronym":"CARPALL","url":"https://clinicaltrials.gov/study/NCT02443831","created_at":"2021-01-18T11:42:34.871Z","updated_at":"2024-07-02T16:35:00.037Z","phase":"Phase 1","brief_title":"CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies","source_id_and_acronym":"NCT02443831 - CARPALL","lead_sponsor":"University College, London","biomarkers":" ABL1 • BCR • KMT2A • IGH • CD22 • TCF3","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["ABL1 • BCR • KMT2A • IGH • CD22 • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2036","study_completion_date":" 12/31/2036","last_update_posted":"2024-05-30"},{"id":"d7ed8a2f-8937-4cbd-aa4d-ea29935f9c24","acronym":"","url":"https://clinicaltrials.gov/study/NCT04195633","created_at":"2021-01-18T20:26:55.926Z","updated_at":"2024-07-02T16:35:01.612Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","source_id_and_acronym":"NCT04195633","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-23"},{"id":"9c213731-a632-4c0f-8af9-a477196f1cb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805605","created_at":"2023-04-10T14:03:04.592Z","updated_at":"2024-07-02T16:35:05.582Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","source_id_and_acronym":"NCT05805605","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/22/2027","primary_completion_date":" 10/22/2027","study_txt":" Completion: 10/22/2028","study_completion_date":" 10/22/2028","last_update_posted":"2024-05-07"},{"id":"c0c1d749-be49-44e4-a22c-cd71bfbd84c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04191187","created_at":"2021-01-18T20:25:39.923Z","updated_at":"2024-07-02T16:35:06.141Z","phase":"Phase 2","brief_title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","source_id_and_acronym":"NCT04191187","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 02/11/2024","primary_completion_date":" 02/11/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-03"},{"id":"f1ad940d-0158-42e2-8647-51b32c5f7ee6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05565417","created_at":"2022-10-04T15:57:50.214Z","updated_at":"2024-07-02T16:35:06.273Z","phase":"Phase 1/2","brief_title":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05565417","lead_sponsor":"Immunitas Therapeutics","biomarkers":" KRAS • BRAF • ALK • PIK3CA • MET • MSI","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation","tags":["KRAS • BRAF • ALK • PIK3CA • MET • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • IMT-009"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 11/28/2022","start_date":" 11/28/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-03"},{"id":"5d576388-a550-4b35-b698-5134873cd7dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03793140","created_at":"2021-01-18T18:45:13.009Z","updated_at":"2024-07-02T16:35:08.385Z","phase":"Phase 2","brief_title":"A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations","source_id_and_acronym":"NCT03793140","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bylantra (devimistat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/31/2018","start_date":" 12/31/2018","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-22"},{"id":"4709cf4b-f7f6-4c8f-8b77-5a8ac8771021","acronym":"","url":"https://clinicaltrials.gov/study/NCT03674411","created_at":"2021-01-18T18:01:23.529Z","updated_at":"2024-07-02T16:35:10.273Z","phase":"Phase 2","brief_title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","source_id_and_acronym":"NCT03674411","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type","tags":["FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 06/23/2020","primary_completion_date":" 06/23/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-10"},{"id":"3bee5af3-3218-464d-93d6-70a26d82e691","acronym":"","url":"https://clinicaltrials.gov/study/NCT02992522","created_at":"2021-01-18T14:43:11.871Z","updated_at":"2025-02-25T14:37:02.856Z","phase":"Phase 1","brief_title":"Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02992522","lead_sponsor":"Beth Christian","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • lenalidomide • Gazyva (obinutuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/21/2017","start_date":" 02/21/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-09"},{"id":"015bee1f-dfaa-4768-9837-b466448d181f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06340737","created_at":"2024-04-01T19:42:38.783Z","updated_at":"2024-07-02T16:35:11.716Z","phase":"Phase 1","brief_title":"AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas","source_id_and_acronym":"NCT06340737","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/29/2024","start_date":" 03/29/2024","primary_txt":" Primary completion: 04/01/2031","primary_completion_date":" 04/01/2031","study_txt":" Completion: 04/01/2031","study_completion_date":" 04/01/2031","last_update_posted":"2024-04-03"},{"id":"acdeafe3-7008-41f0-8f96-f453b266a334","acronym":"","url":"https://clinicaltrials.gov/study/NCT01588015","created_at":"2021-01-18T06:46:27.904Z","updated_at":"2024-07-02T16:35:12.025Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT01588015","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" PD-1 expression","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/29/2012","start_date":" 10/29/2012","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2024-04-02"},{"id":"d9205d85-be27-4b6c-84a5-c85c6627b25a","acronym":"NCI-2018-01198","url":"https://clinicaltrials.gov/study/NCT03136146","created_at":"2021-01-18T15:27:28.397Z","updated_at":"2024-07-02T16:35:12.329Z","phase":"Phase 2","brief_title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","source_id_and_acronym":"NCT03136146 - NCI-2018-01198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-03-29"},{"id":"f7ccd756-4413-4530-bc65-1188b9dc3cbc","acronym":"DIAL","url":"https://clinicaltrials.gov/study/NCT03038672","created_at":"2021-01-18T14:57:44.271Z","updated_at":"2024-07-02T16:35:20.479Z","phase":"Phase 2","brief_title":"Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas","source_id_and_acronym":"NCT03038672 - DIAL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • TMB • BCL2 • BCL6 • CD27 • IRF4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD27 expression","tags":["ALK • TMB • BCL2 • BCL6 • CD27 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD27 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • varlilumab (CDX 1127) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 05/26/2023","primary_completion_date":" 05/26/2023","study_txt":" Completion: 10/25/2024","study_completion_date":" 10/25/2024","last_update_posted":"2024-02-07"}]